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Purpose
Lung cancer is strongly associated to tobacco smoking. However, global statistics estimate
that in females the proportion of lung cancer cases that is unrelated to tobacco smoking
reaches fifty percent, making questionable the etiology of the disease. 
Materials and Methods
A never-smoker female with primary EGFR/KRAS/ALK-negative squamous cell carcinoma
of the lung and their normal sibs were subjected to a novel integrative “omic” approach using
a pedigree-based model for discovering genetic factors leading to cancer in the absence of
well-known environmental trigger. A first-step whole-exome sequencing on tumor and normal
tissue did not identify mutations in known driver genes.  Building on the idea of a germline
oligogenic origin of lung cancer, we performed whole-exome sequencing of DNA from 
patients’ peripheral blood and their unaffected sibs. Finally, RNA-sequencing analysis in 
tumoral and matched non-tumoral tissues was carried out in order to investigate the clonal
profile and the pathogenic role of the identified variants. 
Results
Filtering for rare variants with Combined Annotation Dependent Depletion (CADD) > 25 and
potentially damaging effect, we identified rare/private germline deleterious variants in 11
cancer-associated genes, none of which, except one, shared with the healthy sib, pinpointing
to a “private” oligogenic germline signature. Noteworthy, among these, two mutated genes,
namely ACACA and DEPTOR, turned to be potential targets for therapy because related to
known drivers, such as BRCA1 and EGFR. 
Conclusion
In the era of precision medicine, this report emphasizes the importance of an “omic” 
approach to uncover oligogenic germline signature underlying cancer development and to
identify suitable therapeutic targets as well.
Key words
Exome, Squamous cell carcinoma, 
High-throughput nucleotide sequencing, Disease susceptibility,
Multifactorial inheritance, Precision medicine
Margherita Baldassarri, MD1,2
Chiara Fallerini, PhD1
Francesco Cetta, MD3
Marco Ghisalberti, MD4
Cristiana Bellan, MD5
Simone Furini, PhD6
Ottavia Spiga, PhD7
Sergio Crispino, MD8
Giuseppe Gotti, MD4
Francesca Ariani, PhD1,2
Piero Paladini, MD4
Alessandra Renieri, MD, PhD1,2
Elisa Frullanti, PhD1
+  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  
+  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  
+  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +
+  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  
+  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  
+  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +
+  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  
+  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +
+  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +
+  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  
+  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +
+  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +
+  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  
+  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +
+  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +
Correspondence: Alessandra Renieri, MD, PhD
Medical Genetics Unit, University of Siena,
Azienda Ospedaliera Universitaria Senese, 
Viale Bracci, 2 - 53100 Siena, Italy
Tel: 39-0577-233303 
Fax: 39-0577-233325
E-mail: alessandra.renieri@unisi.it
Received  March 9, 2017
Accepted  April 25, 2017
*Margherita Baldassarri and Chiara Fallerini 
contributed equally to this work.
1Medical Genetics Unit, University of Siena,
Siena, 2Genetica Medica, Azienda 
Ospedaliera Universitaria Senese, Siena,
3IRCCS MultiMedica, Milan, 
4Thoracic Surgery Unit, Azienda 
Ospedaliera Universitaria Senese, Siena, 
5Section of Pathology, Department of 
Medical Biotechnology, Departments of 
6Medical Biotechnology and 7Biotechnology,
Chemistry and Pharmacy, University of Siena,
Siena, 8Medical Oncology Unit, 
Azienda Usl Toscana Sudest, Siena, Italy
Cancer Res Treat. 2017 May 26 [Epub ahead of print] 
2 CANCER  RESEARCH  AND  TREATMENT
Introduction
Lung cancer is an important public health problem and the
leading cause of cancer death worldwide [1]. The two major
histological types of lung cancer are non-small cell lung can-
cers (NSCLC) and small cell lung cancers. NSCLCs consist
mostly of lung adenocarcinomas (ADCA) and lung squa-
mous cell carcinomas (SQCC). These two NSCLC subtypes
have both unique and common clinical and histopathological
characteristics. For example, ADCAs are mainly observed in
never smokers [2] while SQCC is the most frequent histolog-
ical type among smoking patients.
The discovery of common, mutually exclusive, driver
genes, epidermal growth factor receptor (EGFR), KRAS
proto-oncogene GTPase (KRAS) and anaplastic lymphoma
receptor tyrosine kinase (ALK), that represent crucial thera-
peutic targets, led to a remarkable improvement in NSCLC
therapy. However, only about 50% of NSCLC acquire muta-
tions in these genes. Identification of new cancer driver genes
currently is a top research priority. Recent studies using next-
generation sequencing (NGS) approach characterized
NSCLC tissues in order to identify new less common candi-
date driver mutations [3,4] highlighting the presence of great
variability even within tumor samples belonging to the same
histological type.
Up to now, application of NGS technology has been 
reported in many lung cancer samples leading to the discov-
ery of a large set of new somatic mutations in key cancer
genes. Nevertheless, no studies are present in literature that
performed whole exome sequencing (WES) and RNA-
sequencing (RNA-seq) from tumoral and matched non-
tumoral lung tissues integrating these with WES of blood
DNA from the same individual to identify possible tumor-
driver variants which are already present in the germline
background and that may predispose to lung cancer. Using
WES analysis in a model of cases and controls deriving from
the same kindred—discordant sib-pair design—we have 
recently showed that a set of oligogenic germline mutations,
that are detectable in the peripheral blood, may play a role
in the development and growth of lung ADCA in never
smokers [5]. Noteworthy, our previous results demonstrated
that the oligogenic cancer predisposing signature is a “pri-
vate signature,” varying from one patient to another.
Herein, we tested further the hypothesis of the oligogenic
origin of lung cancer in a never-smoker female who devel-
oped a SQCC of the lung. We applied for the first time an 
integrative “omic” approach of WES and RNA-seq experi-
ments in a discordant sib-pair design. 
Materials and Methods
1. Samples and DNA/RNA extraction
Patient and sib signed the informed consent declaration at
the Medical Genetics Unit of the Azienda Ospedaliera Uni-
versitaria Senese, Italy, for the use of their biological samples
and clinical data for research purposes. The study protocol
was approved by the Ethical Committee of the Azienda 
Ospedaliera Universitaria Senese. Information on histologi-
cal diagnosis (by the Pathology Unit) was retrieved from the
clinical records. Genomic DNA of patient and healthy sib
was isolated from EDTA peripheral blood using QIAamp
DNA Blood Kit (Qiagen, Hilden, Germany) according to the
manufacturer’s protocol. Formalin-fixed paraffin-embedded
(FFPE) samples of patient’s tumoral and non-tumoral lung
tissues were obtained from the Pathology Unit of the recruit-
ing hospital and analyzed through WES and RNA-seq. DNA
was extracted from FFPE lung tumoral and non-tumoral tis-
sue samples using MagCore Genomic DNA FFPE One-Step
Kit for MagCore System (Diatech Pharmacogenetics s.r.l., 
Ancona, Italy). RNA was extracted from FFPE lung tumoral
and non-tumoral tissue samples of our case using High Pure
FFPE-Tissue RNA Isolation Kit (Roche, Basel, Switzerland)
following the manufacturer’s instructions. Additional RNAs
from three FFPE lung non-tumoral tissues from other lung
cancer patients were isolated using the same kit and used as
control tissues. RNA samples were processed to remove
rRNA using Ribo-Zero rRNA Removal Kit for Human sam-
ples (Illumina, Grand Island, NY) following the manufac-
turer’s instructions. RNA integrity was verified using the
Agilent Eukaryote Total RNA Nano Kit (Agilent Technolo-
gies, Palo Alto, CA) on Agilent2100 Bioanalyzer (Agilent
Technologies).  Both DNA and RNA were quantified by
spectrophotometry (ND-2000c, NanoDrop Products, Wilm-
ington, DE) and Qubit Fluorometer with Qubit dsDNA HS
Assay and Qubit RNA HS Assay Kits (Life Technologies,
Carlsbad, CA), respectively.
2. WES and data analysis
WES was performed using the Life Technologies Ion Pro-
ton sequencer (Life Technologies) on genomic DNA samples
of cases and controls and tumor tissues as previously 
described [6]. Variant were then annotated against external
datasets, including 1000 genomes (http://www.1000geno-
mes.org/) and dbSNP. After removing variants with low
coverage, in order to identify candidate susceptibility vari-
ants, we selected for rare variants with minor allele fre-
quency [MAF] ≤ 0.01 or not reported (S1 Fig.). We then
filtered excluding variants with clinical significance as 
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“benign” or “likely benign” and present in an in-house data-
base of variants. Additional filtering procedures were thus
implemented for retrieving exonic rare variants with a 
potential detrimental impact on protein function, i.e., vari-
ants, insertions and deletions (indels) causing exonic
frameshifts and missense variants predicted as deleterious
applying the Combined Annotation Dependent Depletion
(CADD > 25) and the MetaSVM (Support Vector Machine)
bioinformatics tools. Genes affected by mutations were
checked in literature in order to identify cancer-related genes.
Validation of these variants was carried out using custom
NGS panel for Ion PGM sequencer (Life Technologies). 
3. RNA-seq and data analysis
RNA-seq was performed using Illumina HiSeq2500 plat-
form (Illumina Inc., San Diego, CA), in a 2×100 bp paired-
end configuration in High Output mode (V4 chemistry), with
a total of at least 250 million reads per lane. After quality
check, RNA (50 ng) was used to prepare sample libraries. 
Sequencing library construction included these steps: library
construction using Illumina TruSeq RNA Sample Pre Kit 
(Illumina), library purification using Beckman AMPure XP
beads (Beckman Coulter s.r.l., Milan, Italy), insert fragments
test using Agilent High Sensitivity DNA Kit on Agilent 2100
Bioanalyzer (Agilent Technologies), and cBOT automatic
cluster (TruSeq PE Cluster Kit v3-cBotHS). Post-library qual-
ity controls were performed using the Agilent RNA 6000
Nano kit (Agilent Technologies) on Agilent 2100 Bioanalyzer
(Agilent Technologies) and Qubit Fluorometer (Life Tech-
nologies).  Libraries were then loaded on HiSeq2500 sequenc-
ing platform (Illumina) and sequenced using 2×100 bp
pair-end High Output Mode (V4 chemistry) per lane. The
reads generated on the HiSeq2500 were provided under
FASTQ format. 
Sequence reads in FASTQ format were processing using
the Fastqc software (http://www.bioinformatics.babraham.
ac.uk/projects/fastqc/) for data quality check and removing
excess adaptors to get high-quality and clean reads. The
high-quality reads were aligned to the GRCh38/hg38 refer-
ence human genome (ftp://jgi-psf.org/pub/compgen/phy-
to zome/v9.0/Ptrichocarpa/assembly/Ptrichocarpa_210.fa.
gz) using the TopHat software ver. 2.0.9 [7]. Transcript 
assembling and expression quantification were carried out
using Cufflinks ver. 2 [8]. Gene expression was expressed as
fragments per kilo-base transcript per million mapped reads
(FPKM) value. This normalized value was used for visuali-
zation on a genome browser (http://genome.ucsc.edu/), as
well as to compare read coverage between and throughout
different genes. Statistical analysis was performed to com-
pute the mean FPKM level with the associated p-value for
lung normal tissues together with the mean FPKM level with
the associated p-value for lung cancer tissues. Cuffdiff tool
from Cufflinks was used to identify differentially expressed
genes [9]. Gene Ontology and pathways analyses were per-
formed using both Enrichr (http://amp.pharm.mssm.edu/
Enrichr/) and Database for Annotation, Visualization and
Integrated Discovery functional annotation tool (DAVID
Bioinformatics Resources 6.7, https://david.ncifcrf.gov).
Results
1. Patient description
A still alive Caucasian female patient, who developed SQCC
of the lung in the absence of smoking habit and/or asbestos
exposure, was recruited. Her smoker father died at age 63
from lung cancer. She had no known other family history of
cancers. At age of 77, after a “screening” chest and abdomen
computed tomography scan examination, a 12×7 mm nodule
was found in the dorsal segment of the right superior lobe in
association with a small “ground glass” area (9.5 mm in diam-
eter) in the left superior lobe. The nodule showed a small vol-
umetric increase after 3 months and the patient was scheduled
for surgery at the Thoracic Surgery Unit of Azienda Ospe-
daliera Universitaria Senese, Italy. Intraoperative diagnosis
was NSCLC. At gross pathologic examination, a 12×0.5 solid
nodule with irregular margin was detected. Histologic exam-
ination showed SQCC with a mainly perialveolar and perivas-
cular growth pattern. Tumoral cells were p63+, cytokeratin
(CK) 5/6+, CK7‒, thyroid transcription factor 1‒, synapto-
physin‒, chromogranin‒. Ki67 immunostaining was 20 per
cent. There was moderate infiltration of the visceral pleura,
but no lymphonodal infiltration. Two years before, patient had
undergone to removal of a cutaneous nodule located in the
left side of the neck that resulted to be a SQCC of the basal
subtype. She subsequently underwent left cervical lym-
phadenectomy, that showed infiltration of three cervical lym-
phonodes. On the basis of histological analysis, site of tumors
and type of lymphonodal involvement, it was stated that the
patient had two different primary tumors, both belonging to
the squamous subtype. The patient is alive and well 4 years
after the first and 2 years after the second operation.  
2. “Omic” characterization
We firstly carried out whole-exome sequencing of gDNA
from FFPE tumoral and non-tumoral lung tissue. With the aim
of identification of somatic driver mutations, we subtracted
the germline background to 39,286 variants present in the 
tumoral lung tissue, leading to 2,543 exonic variants present
only in the tumor. Among them, 1,381 were missense variants
and 254 were truncating (S2A Fig.). We then extracted the 
somatic mutational signature according to base substitutions,
as described by Alexandrov et al. (2013) [10]. This analysis
showed a predominance of C>T transitions in tumoral lung
tissue, not corresponding to the specific cancer signature 
related to tobacco consumption that are characterized by pre-
dominance of C>A transversions (S2B Fig.).  Pathway analysis
showed that mutations observed in SQCC tissue mostly 
affected genes involved in extracellular matrix organization
(p=0.005), transmembrane transport of small molecules
(p=0.010) and collagen formation (p=0.034) pathway, as pre-
viously reported (S2C Fig.) [4]. Overall, no mutations in the
known driver genes, such as EGFR, KRAS, AKT, ROS1, nor in
other putative driver genes described by Campbell et al. [3]
were present in our tumoral sample [3]. EML4-ALK fusion
gene was also excluded. The failure of identification of somatic
driver mutations rose the hypothesis that germline variants
may have a role in etiology of the disease.
We then adopted a novel integrative “omic” approach using
a combination of NGS techniques in a pedigree model that
compares discordant sibs to test the hypothesis of oligogenic
origin of lung cancer (Fig. 1).
We carried out whole-exome sequencing of gDNA from 
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Fig. 1.  Flowchart illustrating the study strategy and result. WES, whole exome sequencing; EGFR, epidermal growth factor
receptor; CADD, Combined Annotation Dependent Depletion; RNA-seq, RNA sequencing.
WES in tumoral vs. normal tissue
No EGFR, KRAS mutations
No mutations in other putative driver genes
(Campbell et al. [3])
WES patient vs. healthy sib in blood
19 cancer genes with CADD > 25
or truncating mutations
RNA-seq in tumoral vs. normal tissue
11 with altered expression
1
BRCA1
pathway
1
EGFR 
pathway
9
other 
pathway
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Table 1. Expression levels of 11 cancer-related germline variants (fold-change > ±1.5)
Gene
Amino acid Fold- 
Group
symbol
change change Gene function related to cancer development
(CADD value) T/N
Group 1: Underexpressed ACACA p.R650W (33) –4.35 Acetyl-CoA carboxylase alpha has a role in de novo
in tumoral tissue lipogenesis catalyzing the carboxylation of acetyl-CoA to
(fold-change ≤ 0.66) malonyl-CoA. The enzyme is under long term control at
the transcriptional and translational levels. It is known to
specifically interact with BRCA1 [11].
MYH9 p.Q843P (31) –1.64 Myosin heavy chain 9 is a myosin IIA heavy chain that 
interacts with β-actin to maintain cytoskeleton integrity. 
It is a EGFR-associating protein in NSCLC cell lines 
overexpressing EGFR [12].
CTSZ p.V120M  (26) –1.59 Cathepsin Z is a lysosomal cysteine proteinase. CTSZ is 
mostly expressed in immune cells, such as macrophages 
and monocytes, and involved in antigen processing and 
maturation of the major histocompatibility complex class 
II molecules [13]. This gene is expressed ubiquitously in 
cancer cell lines and primary tumors.
Group 2: Underexpressed AVL9 p.R13fs (NA) –3.13a) AVL9 cell migration associated is among the 73 cancer 
in both normal and driver candidate genes previously identified via 
tumoral tissue dog-human comparison, deleted in colorectal cancer [14] 
(fold-change ≤ 0.66) and classified as putative tumor suppressors. 
AVL9-depletion inhibits the migration of A549 human 
adenocarcinomic alveolar basal epithelial cells [15].
CARS p.G259S (33)b) –3.03a) Cysteinyl-tRNA synthetase is one of several located near 
the imprinted gene domain on chromosome 11p15.5, 
an important tumor-suppressor gene region [16].
DEPTOR p.R211X (46) –1.96a) DEP-domain containing mTOR interacting protein has 
growth suppression activity against pancreatic cancer 
cells, and its expression is gradually lost during pancreatic 
tumorigenesis [17]. Tumor progression mediated by 
EGFR ectopic expression was diminuished by transfection 
with DEPTOR in lung adenocarcinoma. Gefitinib, 
a specific EGFR inhibitor used for lung cancer therapy, 
stimulated DEPTOR accumulation [18].
Group 3: Overexpressed PSCA p.W109X (NA)b) 391.96 Prostate stem cell antigen encodes a 
in tumoral tissue glycosylphosphatidylinositol-anchored cell membrane 
(fold-change ≥ +1.5) glycoprotein that is upregulated in a large proportion of 
prostate cancers and other cancers. It is highly expressed 
in non-small cell lung cancer and may be functionally 
important for the disease: small interfering 
RNA-mediated knockdown of PSCA resulted in the 
inhibition of LC growth [19].
ENO3 p.YT214X (35) 7.04 Enolase 3 encodes one of the three enolase isoenzymes. 
It was found upregulated in liver cancer mouse model [20]. 
PARP14 p.E587fs (NA) 4.93 Poly(ADP-ribose) polymerase family member 14 is an 
anti-apoptotic protein that may regulate aerobic glycolysis 
and promote survival of cancer cells [21]. Its increased 
expression has been reported in a variety of tumor types.
CTBP2 p.R717C (34) 4.34 C-terminal binding protein 2 is upregulated in a number of 
tumors, such as hepatocellular carcinoma, prostate cancer, 
and gliomas [22,23].
peripheral blood of the SQCC patient and her unaffected sib
as controls (S3 Table). Overall, we identified 37,727 germline
variants in the patient and 37,355 germline variants in the
healthy sib and 39,286 variants in the tumoral lung tissue.
To identify susceptibility variants, we compared case and
control WES data and selected for rare variants (MAF ≤ 0.01)
with a potentially damaging effect: truncating variants, i.e., 
insertions and deletions (indels) causing exonic frameshifts
and nonsense mutation, and missense deleterious variants
predicted with CADD > 25 and filtering out those with
MetaSVM as “tolerated” (S1 Fig.). We obtained 111 potential
deleterious variants of which 40 were shared by both siblings.
Among the 111 potentially deleterious variants, 19 variants
mapped in genes that have been found previously associated
with cancer of the lung or other tissues (S4 Table). Validation
of these variants led to the confirmation of all variants that
were probably responsible for lung cancer susceptibility in our
case. All the sequence variants identified were in the heterozy-
gous state and were also present in the relative lung tumor tis-
sue in heterozygous state as expected.
Finally, we performed RNA-seq analysis of RNA extracted
from both FFPE tumoral and non-tumoral lung tissues of our
patient in order to detect differences in the expression level
that could help the understanding of the functional role of
germline variants. RNA-seq generated a mean of 75,134,860
reads per sample (S5 Table). 
To assess the potential functional role of the 19 germline
cancer-related variants identified by whole-exome sequencing
in the patient and predicted as deleterious by bioinformatics
tools, we combined results from WES experiments with the
respective-gene expression profile from RNA-seq of non-
tumoral and matched tumoral tissue. In 19 variants mapping
in 19 genes, RNA-seq data showed differential expression
level (fold-change > ±1.5) for 11 genes, reinforcing the patho-
genic role of the identified variants showing three different 
effects (Table 1). Three genes, namely ACACA, CTSZ, and
MYH9, showed downregulation in lung cancer compared to
normal tissue. Three genes, namely DEPTOR, AVL9, and
CARS, showed downregulation of both normal and cancer tis-
sue when we compared those tissues with a pool of three nor-
mal lung tissues. Lastly, five remaining genes (PSCA, ENO3,
PARP14, CTBP2, FOXM1) showed an upregulation in lung
cancer tissue. All the above mentioned variants were exclusive
of the patient with the exception of variant in FOXM1 gene
that was present also in the healthy sib. 
Among the 11 germline-mutated cancer-related genes, two
genes, namely ACACA and DEPTOR, are known to be associ-
ated with the known driver genes, BRCA1 and EGFR, respec-
tively. In particular, we found a missense variant, that has
been predicted as deleterious, c.C1948T, p.Arg650Trp (NM_
198837.1, exon 16) in ACACA gene (OMIM* 200350) encoding
Acetyl-CoA carboxylase alpha, the rate-limiting enzyme for
the long-chain fatty acid synthesis [25]. The other mutation is
a stopgain variant c.A631T, p.Arg211* in DEPTOR gene
(OMIM *612974) encoding DEP domain-containing MTOR-
interacting protein.
Interestingly, from RNA-seq data, we found a decreased 
expression level of ACACA in tumoral rather that in non-
tumoral tissue. Sequence information was extracted from
RNA-seq to confirm the presence of mutated mRNA and we
found that 81.8% of reads carried the mutated allele pinpoint-
ing to a loss of heterozygosity (LOH) effect. The same analysis
Cancer Res Treat. 2017 May 26 [Epub ahead of print] 
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Table 1. Continued
Gene
Amino acid Fold- 
Group
symbol
change change Gene function related to cancer development
(CADD value) T/N
FOXM1 p.P658L (27)b) 3.28 Forkhead box M1 is a transcriptional activator involved in 
cell proliferation. Consistent with an important role of 
Foxm1 in cell cycle progression, increased expression of 
Foxm1 was found in many human tumors. Increased 
Foxm1 expression in human lung adenocarcinomas and 
squamous cell carcinomas was associated with increased 
proliferation of tumor cells [24].
CADD, Combined Annotation Dependent Depletion; T, tumoral lung tissue; N, non-tumoral lung tissue; ACACA, acetyl-
CoA carboxylase alpha; EGFR, epidermal growth factor receptor; NSCLC, non-small cell lung cancers; mTOR, mammalian
target of rapamycin; NA, not applicable; LC, lung cancer; MAF, minor allele frequency. a)Fold-change calculated by comparing
expression levels of normal and tumor tissues with those of a pool of normal lung tissues, b)All listed variants were private
except those in CARS (MAF=0.002), PSCA (MAF=0.0076), and FOXM1 (MAF=0.0044) genes.
revealed a decreased expression level of DEPTOR both in nor-
mal and tumoral tissue at mRNA level pinpointing to LOH 
effect already present in the surrounding normal tissue.
Discussion
Among 111 potentially deleterious germline variants, 19
mapped in genes that have previously been associated with
cancer of the lung or other tissues (S3 Table). Using the dis-
cordant-sib pair design, we confirmed the presence of an oli-
gogenic signature present in the patient’s genetic back-
ground [5]. In fact, only one out of 11 cancer-related variants
was also found in the healthy sib. For all the 11 variants,
RNA-seq data reinforced the pathogenic role showing three
different effects on the expression levels of harboring gene:
three genes (ACACA, CTSZ, MYH9) showed a possible “sec-
ond hit” in tumor suppressor genes responsible for gene 
inactivation; three genes (AVL9, DEPTOR, CARS) showed a
possible transcript instability occurring in both tumoral and
normal mutation-bearing tissues; five genes (PSCA, ENO3,
PARP14, CTBP2, FOXM1) were upregulated in lung cancer
tissue confirming previous published results and suggesting
their role as oncogene. No mutations or gene expression 
alteration in genes belonging to the Hedgehog pathway,
mainly involved in basal cell carcinoma development, were
found in our case.
The oligogenic combination of cancer predisposing genes
found in our patient supports the model of “private genetic
epidemiology” for lung cancer susceptibility [5]. In fact, we
found that 11 cancer-related genes were mutated in the 
patient and only one in healthy sib (Fig. 2), suggesting that
the oligogenic control of lung cancer susceptibility is due to
a peculiar signature of multiple germline mutations in can-
cer-related genes probably with a dosage effect. This per-
sonal signature may play a role in the development and
growth of lung cancer and, therefore explain the non-hered-
itability of the condition, especially in non-smokers patients. 
Focusing our analysis on genes that have already been 
reported in association with known druggable target genes—
and likely having a major role in driving tumor development
in our case—, we identified two possible suitable targets.
Acetyl-CoA carboxylase alpha (ACACA) is a key enzyme in
de novo lipogenesis catalyzing the carboxylation of acetyl-
CoA to malonyl-CoA. ACACA is known to be one of the
major BRCA1-interacting protein [11]. Cancer cells strongly
need to de novo synthesize fatty acid for membrane and 
energy production [26] and interaction between ACACA and
BRCA1 is likely to be important for BRCA1-mediated tumor
suppressor activity [27]. BRCA1 indeed binds the phospho-
rylated and inactive form of ACACA and this interaction
blocks ACACA activity by preventing its dephosphorylation
[14]. The identified variant c.C1948T, p.Arg650Trp is outside
the catalytic domain but may have a role in folding of 
domain conformation determining a different exposure for
BRCA1 binding. Based on the evidence that in our tumoral
tissue only the mutated transcript is present, we can assume
that, even if protein level is decreased, the isoform loses neg-
ative control by BRCA1 and remains active. In this case, 
patient could potentially benefit from a therapy with
ACACA inhibitors such as miR-195 [28] or soraphen A [29]
(Fig. 3A). 
The second druggable variant maps in DEPTOR gene,
whose loss determines the activation of mammalian target
of rapamycin (mTOR) cascade and promotes cell growth and
survival. It is known that DEPTOR mainly acts as a tumor
suppressor [17,30]. A recent study in lung cancer demon-
strated that activation of EGFR signaling resulted in down-
regulation of DEPTOR expression. In the same study, tumor
progression mediated by EGFR ectopic expression was dimi-
nished by transfection with DEPTOR in lung adenocarci-
noma cell lines and that treatment with gefitinib, an EGFR
tyrosine kinase inhibitor, stimulated DEPTOR expression
leading to a significantly decreased cell proliferation, migra-
tion and invasion [18]. In line with these results, we observed
an increased expression level of DEPTOR in normal and 
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Fig. 2.  Pedigree of the two sib-pairs and representation of
disruptive mutations in cancer-related genes found in the
patient and in her unaffected sib.
Patient
Age at diagnosis: 77 yr
Healthy sib
Age at sampling: 76 yr
ACACA : p.R650W
CTSZ : p.V120M
MYH9 : p.Q843P
AVL9 : p.R13fs
DEPTOR : p.R211X
CARS : p.G259S
PSCA : p.W109X
ENO3 : p.YT214X
PARP14 : p.E587fs
CTBP2 : p.R717C
FOXM1 : p.P658L
FOXM1 : p.P658L
tumoral tissue, suggesting an enhanced predisposition of 
activation of mTOR signaling and thus a promotion of tumor
progression (Fig. 3B). These results suggested the possibility
to use gefitinib in our patient in order to restore DEPTOR
level and consequently suppress cell growth and survival.
In summary, we suggest that both “primary” SQCC are
triggered by the presence of an oligogenic germline signature
consisting of at least 11 mutations, among which two lead to
the activation of mTOR and BRCA1. Thus, this finding opens
up the possibility of treating one of them with an already
commercially available drug and the other with developing
molecules.
This study has a number of limitations. First, alterations in
non-coding regions and copy number variants would have
been missed by our approach. Another limitation is that we
focused only on cancer-associated genes, but we cannot 
exclude that non-cancer genes, in particular those involved
in immune system or drug metabolism, could play a role in
cancer development. Finally, additional functional studies
will be required to translate our results into effective person-
alized therapy. 
The present report provides evidence that an “omic” 
sequencing approach in cancer patient is feasible, and could
impact on treatment decisions, namely in patients not suit-
able for conventional therapy. In the present era of “precision
medicine”, our study demonstrates the utility of applying
this comprehensive sequencing protocol in order to effec-
tively identify possible therapeutic targets enabling person-
alized therapies. 
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Fig. 3.  Likely personal germline driver genes in present case and possible therapeutic options. ACACA (A) and DEPTOR (B)
pathway involvement. ACACA, acetyl-CoA carboxylase alpha; EGFR, epidermal growth factor receptor; PI3K, phospho-
inositide 3-kinase; mTOR, mammalian target of rapamycin.
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